According to a recent LinkedIn post from Tomoverse Imaging Inc, co‑founder Pascal Thériault‑Lauzier participated on stage at the EuroPCR conference in Paris. The post indicates he led a session focused on optimal imaging projections for bifurcation percutaneous coronary intervention, framed as a practical, peer‑to‑peer exchange with leading interventional cardiologists.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The post suggests Tomoverse is positioning itself closely with the interventional cardiology community and complex PCI workflows, which are core markets for advanced cardiac imaging solutions. For investors, this type of expert‑level engagement may signal ongoing clinical validation efforts, potential for deeper KOL relationships, and future commercialization opportunities in the medtech and cardiac imaging segments.
The emphasis on being part of the professional conversation, rather than on specific products or sales, points to an early‑stage or ecosystem‑building focus. While no direct revenue impact can be inferred from the post, sustained visibility at major forums like EuroPCR could enhance brand recognition, support future partnerships with hospitals or device makers, and ultimately influence Tomoverse’s competitive position in cardiac imaging.